Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 21.5% – Should You Buy?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) were up 21.5% on Monday . The company traded as high as $8.15 and last traded at $8.01. Approximately 30,862,008 shares were traded during mid-day trading, an increase of 149% from the average daily volume of 12,371,136 shares. The stock had previously closed at $6.59.

Wall Street Analyst Weigh In

Several research firms recently weighed in on RXRX. Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Wednesday. Jefferies Financial Group dropped their price target on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Tuesday, September 3rd. Finally, Leerink Partners dropped their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research report on Tuesday, September 3rd. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $9.25.

Recursion Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The business has a 50-day simple moving average of $6.67 and a 200-day simple moving average of $7.29. The firm has a market capitalization of $2.24 billion, a PE ratio of -4.88 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $26.08 million during the quarter, compared to analysts’ expectations of $12.62 million. During the same quarter in the previous year, the company posted ($0.43) earnings per share. The company’s quarterly revenue was up 147.6% compared to the same quarter last year. Equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Insider Transactions at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 20,000 shares of Recursion Pharmaceuticals stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $6.16, for a total transaction of $123,200.00. Following the completion of the transaction, the chief executive officer now owns 762,656 shares in the company, valued at approximately $4,697,960.96. This trade represents a 2.56 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, October 8th. The shares were sold at an average price of $6.32, for a total value of $94,800.00. Following the transaction, the chief financial officer now owns 1,426,506 shares of the company’s stock, valued at $9,015,517.92. The trade was a 1.04 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 119,235 shares of company stock valued at $802,988 in the last quarter. 15.75% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Franklin Resources Inc. raised its position in shares of Recursion Pharmaceuticals by 58.9% during the 3rd quarter. Franklin Resources Inc. now owns 18,963 shares of the company’s stock valued at $127,000 after buying an additional 7,027 shares during the period. Sanctuary Advisors LLC acquired a new position in Recursion Pharmaceuticals during the third quarter worth $89,000. Geode Capital Management LLC raised its stake in shares of Recursion Pharmaceuticals by 13.7% in the third quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock valued at $35,803,000 after acquiring an additional 656,003 shares in the last quarter. Barclays PLC raised its stake in shares of Recursion Pharmaceuticals by 53.9% in the third quarter. Barclays PLC now owns 697,432 shares of the company’s stock valued at $4,596,000 after acquiring an additional 244,278 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new stake in shares of Recursion Pharmaceuticals in the third quarter valued at $692,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.